Esperion Therapeutics' aggressive commercialization efforts have significantly boosted retail prescriptions and broadened ...
BASKING RIDGE, N.J., November 13, 2024--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) will highlight new clinical research and ...
AstraZeneca, Daiichi Sankyo seek US FDA’s accelerated approval for datopotamab deruxtecan to treat advanced EGFR-mutated NSCLC ...
Qu – which according to Parsa is the fruit of a collaboration between a global team of experienced AI scientists, ...
AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...
This system offers new capabilities for both clinical imaging and neuroscience with the... at 08:05 Daiichi Sankyo to Showcase TURALIO® Research in Patients with Tenosynovial Giant Cell Tumor at CTOS ...
This system offers new capabilities for both clinical imaging and neuroscience with the... at 08:05 Daiichi Sankyo to Showcase TURALIO® Research in Patients with Tenosynovial Giant Cell Tumor at CTOS ...
AZN beats third-quarter estimates for earnings and sales. It raises its sales and profit outlook for 2024 for the second time ...
Among other major losers, NEXON is plummeting almost 14 percent and Sumitomo Metal Mining is sliding almost 8 percent, while Daiichi Sankyo and JGC Holdings are slipping more than 5 percent each.
Xospata was cleared in the US and Japan last year, and the CHMP backing gives Astellas another leg up in the market over Daiichi Sankyo and its FLT3 inhibitor quizartinib. The EMA is also in the ...
Investor's Business Daily on MSN23h
AstraZeneca Stock Dives As China's Criminal Probe Rattles Its Third-Quarter BeatAstraZeneca beat third-quarter expectations and lifted its guidance Tuesday, but AstraZeneca stock slipped amid a criminal probe in China.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback